Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Aldosterone receptor blockers reduce cardiac-related morbidity and mortality. Recently, we
demonstrated that long-term low-dose spironolactone is clinically safe in many hemodialysis
(HD) patients. In the present study, we assess whether low-dose spironolactone treatment
reduces the high incidence of cardio- and cerebrovascular (CCV) morbidity and mortality in HD
patients. The investigators' hypothesis is that aldosterone receptor blockade by
spironolactone reduces the risk of both CCV morbidity and death among HD patients.
Phase:
Phase 4
Details
Lead Sponsor:
Dialysis Outcomes Heart Failure Aldactone Study Group